Randomized contralateral eye study to evaluate the effect of one-time dosing of NV701 versus commercially available 1.25% pilocarpine solution on pupil size.

开始日期2025-01-30

申办/合作机构

Novus Vision LLC

CTR20244733

/ Recruiting临床3期

盐酸毛果芸香碱滴眼液用于成人老视患者的有效性和安全性的随机、多中心、双盲、安慰剂对照临床试验

以安慰剂为对照，评价盐酸毛果芸香碱滴眼液1.25%用于成人老视患者的有效性和安全性。

开始日期2024-12-24

申办/合作机构

北京福元医药股份有限公司

100 项与盐酸毛果芸香碱相关的临床结果

登录后查看更多信息

100 项与盐酸毛果芸香碱相关的转化医学

登录后查看更多信息

100 项与盐酸毛果芸香碱相关的专利（医药）

登录后查看更多信息

10,996

项与盐酸毛果芸香碱相关的文献（医药）

2025-08-01·AMERICAN JOURNAL OF OPHTHALMOLOGY

Size Matters

Article

作者: Asrani, Sanjay ; Park, Ki Ho

PURPOSE:

To describe the ideal size of a laser iridotomy and discuss its importance.

DESIGN:

Perspective.

METHODS:

Articles in ophthalmology literature on this topic were reviewed, and commentary is provided based on the authors' experiences.

RESULTS:

An ideal laser iridotomy size is 200 microns and larger, especially in eyes with uveitis. The final size of an iridotomy must be confirmed after the effects of the pilocarpine has worn off and the pupil is not being constricted by light. A location of the iridotomy furthest from the lid margin may reduce the chances of dysphotopsias and thus allow for an adequately sized iridotomy.

CONCLUSION:

An iridotomy of an ideal size is needed to reduce the pressure differential on both sides of the iris so as to be effective in eliminating pupillary block.

2025-07-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Novel benzenesulfonamide derivatives linked to diaryl pyrazole tail as potential carbonic anhydrase II/VII inhibitors with anti-epileptic activity

Article

作者: Mohamed, Mamdouh F A ; Fadaly, Wael A A ; Giovannuzzi, Simone ; Abd El-Hameed, Abeer M ; Nemr, Mohamed T M ; Supuran, Claudiu T ; Eldehna, Wagdy M ; Alkabbani, Mahmoud Abdelrahman ; Nocentini, Alessio ; Zidan, Taha H ; Hefina, Mohamed M

Two new series of 1,2,3-triazole benzenesulfonamide derivatives 16a-f and imino-thiazolidinone benzenesulfonamide derivatives 19a-f with diaryl pyrazole tail were synthesized as carbonic anhydrase (CA) II, VII inhibitors and assessed for antiepileptic activity. All compounds were tested in vitro for their inhibition activity against the human (h) carbonic anhydrase I, II, and VII isoforms. Among these series, compounds 16b, 16d, 19b, and 19d exhibited exceptional inhibitory activity against hCA II, with K_i 10.9-47.1 nM, and hCA VII, with K_i 8.4-23.6 nM, while the two series did not show significant activity against hCA I. Furthermore, 16b, 16d, 19b, and 19d were tested against in vivo pilocarpine-induced seizure model, and they showed excellent neuroprotective activity; they delayed seizure onset, reduced seizure severity, and improved survival rates compared to the pilocarpine group, which highlighted their efficacy in regulating neuronal excitability through CA inhibition and chloride homeostasis. Also, hippocampal levels of KCC2 and mTOR were analyzed, as these markers are critical in regulating neuronal excitability and are closely linked to epilepsy. Noteworthy, Compounds 16d and 19b surpassed the standard anti-convulsant valproic acid in key parameters, underscoring their superior efficacy. In addition, they do not show any significant neurotoxic effects or alterations in liver and kidney function. Moreover, the results of in vitro cytotoxicity of compounds 16d and 19b against Vero cells indicate their safety at the doses given (IC₅₀ = 59.7, 71.9 μM respectively) compared to acetazolamide (IC₅₀ = 32.3 μM). Finally, molecular docking of sulfonamide derivatives with hCA II (PDB code: 2h4h) and hCA VII (PDB code: 3ml5) was performed.

2025-05-01·NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

The decline in the clinical relevance of pilocarpine and physostigmine monitored in pharmacology textbooks from 1878 to 2023: nine take-home messages for future (pharmacology) textbook authors

Article

作者: Seifert, Roland ; Ludwig, Laureen

Abstract:

In a recent study, using hydrogen cyanide as paradigm, we have shown that pharmacological knowledge evolves non-linearly (https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/38900251/). The aim of this study was to investigate the changes in the presentation of the drugs pilocarpine and physostigmine in textbooks from 1878 to 2023. The categories of structure, molecular mechanism of action, pharmacokinetics, effects, indications, adverse drug reactions, interactions, and contraindications were evaluated. The pharmacological knowledge on the molecular mechanism, chemical structure, and pharmacokinetics of pilocarpine and physostigmine changed the most during the period of 150 years. Until 1944, textbooks did not mention a molecular mechanism of action of pilocarpine and from 1951 onwards they described the activation of muscarinic acetylcholine receptors as the molecular basis of pilocarpine’s effect. Until 1944, most textbooks on physostigmine also did not mention the molecular mechanism of action. From 1951 onwards, the reversible inhibition of acetylcholinesterase is mentioned as the mechanism of action of physostigmine. In contrast, in the categories effects, indications, adverse drug reactions, interactions, and contraindications, the detected changes in the pharmacological knowledge presented were comparatively smaller. Older pharmacology textbooks were better than newer ones at discussing changes in knowledge and scientific errors. We noted substantial differences in the presentation of pilocarpine and physostigmine among German and US pharmacology textbooks. We show a decline of the clinical relevance of both drugs and their presentation in pharmacological textbooks with physostigmine being virtually irrelevant. But modern textbooks still discuss physostigmine substantially, fitting to studies on the obsolete drug reserpine (https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/38103060/). Thus, textbooks often far lag clinical practice. Google Scholar conveys the incorrect impression that physostigmine is clinically more relevant than it is. An exponential decline in prescription numbers is a robust indicator of clinical obsolescence. From our study, we extract nine easily implementable take-home messages for future (pharmacology) textbook authors to ensure that this traditional teaching format will prevail against the competition of allegedly more “modern” teaching media.

168

项与盐酸毛果芸香碱相关的新闻（医药）

2025-04-14

·GlobeNewswire-Health Care

SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)

DUBLIN, Ireland and OXFORD, United Kingdom, April 14, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to emactuzumab for the treatment of TGCT patients that are not amenable to or who would not benefit from surgery. Emactuzumab, a potentially best-in-class CSF-1 receptor (CSF-1R) inhibiting monoclonal antibody, is currently being evaluated in the TANGENT study, a global, multi-centre, randomized, double-blind, placebo-controlled registrational Phase 3 trial. TGCT is a rare, non-malignant but aggressively growing tumour of the synovium, tendon sheaths and bursa membranes primarily located in knee, hip, and ankle joints and caused by excessive production of CSF-1. It is a chronically debilitating disease for patients causing loss of function of the affected joints, as well as pain, stiffness and limited range of motion. Receipt of FTD for TGCT was supported by data from Phase 1/2 clinical studies demonstrating rapid, robust tumour reduction and durable response combined with a manageable safety profile. Emactuzumab has also previously received Orphan Medicinal Project designation from the European Medicines Agency. “The granting of FTD for emactuzumab in TGCT highlights the devastating toll that this disease has on patients, as well as the critical need that remains for new treatment options,” said Elyse Seltzer, M.D., Chief Medical Officer of SynOx Therapeutics. “Based on our clinical work to date, we believe that emactuzumab has significant potential to address key patient needs by offering an effective, short-course treatment with rapid onset and a durable response that allows individuals suffering from TGCT to better manage their disease and move forward with their lives. We look forward to completing the ongoing TANGENT study and progressing emactuzumab toward potential commercialization.” About Fast Track DesignationThe FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need. Fast Track status allows for enhanced communication and collaboration between the FDA and drug developers, potentially speeding up the delivery of life-saving treatments to patients. About Tenosynovial Giant Cell Tumour (TGCT)Tenosynovial Giant Cell Tumour (TGCT), previously termed pigmented villonodular synovitis (PVNS), is a type of tumour that affects the soft tissue lining of joints and tendons. TGCTs are categorised as fibrohistiocytic tumours by the WHO classification and are subclassified based on growth patterns (localised and diffuse types) and location (tendon sheath, intra- and extra-articular forms). TGCTs are locally destructive and can be aggressive. The disease causes significant joint pain, stiffness, loss of function and reduced quality of life. While most patients undergo surgery, more than 50% of those with diffuse TGCT experience tumour recurrence within three years. If left untreated, TGCT can cause joint deformity, degenerative changes, and even lead to arthrodesis or amputation in severe cases. About CSF-1 and EmactuzumabCSF-1 (or macrophage colony-stimulating factor) is a cytokine that binds to the CSF-1 receptor (CSF-1R), expressed on macrophages and other immune cells. Emactuzumab is a humanised IgG1 monoclonal antibody targeting CSF-1R, designed to inhibit and deplete macrophages in tumour tissue. Originally developed by Roche, emactuzumab has shown substantial efficacy in clinical studies in TGCT, including an objective response rate of ~71%, rapid tumour reduction, functional improvement, and good tolerability with a manageable safety profile. Emactuzumab may also have utility in other macrophage-driven diseases, and SynOx is actively exploring further development opportunities in these areas. Additional details regarding the ongoing registrational Phase 3 TANGENT study can be found on ClinicalTrials.gov (Identifier: NCT05417789). About SynOx TherapeuticsSynOx Therapeutics Limited is a Dublin and Oxford-based, late-stage clinical biopharmaceutical company developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1-related and macrophage-driven disorders. SynOx is led by an experienced team of industry professionals with a successful track record of developing and bringing products to commercialization. The company is backed by a strong syndicate of premier life science investors including Forbion, Gilde Healthcare, HealthCap, Bioqube Ventures and Medicxi. Contacts: SynOx Therapeutics Ray Barlow Chief Executive Officer Tel: +44 (0) 208 058 5619 Email: enquiries@synoxtherapeutics.com Vida Strategic Partners (on behalf of SynOx) Tim Brons (Media) 415-675-7402 tbrons@vidasp.com

快速通道临床3期孤儿药

2025-04-13

·蒲公英Ouryao

【出海新进展】4药品出口海外！

来源：企业公告编辑：wangxinglai2004近日，四药企分别发布了产品海外上市进展公告，具体为甘李药业制剂获巴基斯坦注册批件、浙江奥翔药业原料药获CEP证书、健友生化制剂获FDA批件和浙江东邦药业原料药获韩国注册证书。甘李药业制剂获巴基斯坦注册批件一、药物基本情况药品名称：BASAGINE 药品通用名：甘精胰岛素注射液适应症：糖尿病剂型：注射剂规格：3ml：100IU/ml（卡式瓶）批件号：Reg. No. 120504申请人：甘李药业股份有限公司二、药物其他相情况甘精胰岛素注射液属于长效胰岛素类似物产品，又称基础胰岛素类似物，每天注射一次，注射起效后作用时间可持续24小时。甘精胰岛素具有作用时间长、血药浓度无峰值、平稳地降低患者血糖的作用，有较好的疗效和安全性，因此甘精胰岛素注射液成为糖尿病治疗中尤为重要的基础胰岛素类似物。截至公告发布日，在巴基斯坦境内甘精胰岛素注射液的主要供货商为赛诺菲。赛诺菲作为原研厂家，其甘精胰岛素产品2024年的全球销售额约17.6 亿美元，截至2024 年9月30日，甘李药业在甘精胰岛素项目中累计投入研发费用9.06亿元人民币。浙江奥翔药业原料药获CEP证书一、药物基本情况药品名称：盐酸毛果芸香碱剂型：原料药持有人：浙江奥翔药业股份有限公司证书编号：CEP 2023-367-Rev 00 发证机构：欧洲药品质量管理局（EDQM）二、药物其他相情况盐酸毛果芸香碱最早用于治疗口干症，剂型为片剂。随后盐酸毛果芸香碱被开发为其它剂型，如凝胶剂、滴眼液等，用于治疗开角型青光眼、闭角型青光眼以及高眼压症等。 2021年，艾伯维（Abbvie）旗下公司艾尔建研制的盐酸毛果芸香碱滴眼液（规格1.25%）获美国FDA批准上市，是全球首款用于治疗老视的药物。盐酸毛果芸香碱是M-胆碱受体激动剂，可激活平滑肌的毒蕈碱受体，通过虹膜括约肌的收缩，使瞳孔收缩，以增加焦深，改善近中视力，同时保持瞳孔对光的反应，另外其还可收缩睫状肌，增强适应力，从而达到治疗成人老视的效果。健友生化制剂获FDA批件一、药物基本情况药品名称：利拉鲁肽注射液适应症：作为饮食和运动的辅助手段，改善成人和10岁及以上的儿童2型糖尿病患者的血糖控制。降低伴有心血管疾病的2型糖尿病成人患者的主要心血管不良事件的风险。剂型：注射液规格：18 mg/3 mL (6 mg/mL) ANDA号：218115 申请人：南京健友生化制药股份有限公司二、药物其他相情况利拉鲁肽注射液原研药品，由NOVO NORDISK INC持有，2010年01月25日前经FDA批准在美国上市。经查询，除原研厂家以外，美国境内仅有1家HIKMA PHARMACEUTICALS USA INC同规格的利拉鲁肽注射液获批上市。截至目前公司在利拉鲁肽注射液研发项目上已投入研发费用约人民币5,737.31万元。浙江东邦药业原料药获韩国注册证书一、药物基本情况企业名称：浙江东邦药业有限公司地址：中国浙江省台州市临海市台州湾经济技术开发区东海第五大道21号产品名称：头孢妥仑匹酯 DMF注册号：20250326-209-J-1841 发证机构：韩国食品药品监督管理局（韩国MFDS）二、药物其他相情况头孢妥仑匹酯为第三代头孢类抗菌药物，用于治疗敏感菌引起的呼吸道、泌尿系统、胆道、皮肤软组织感染等。据相关数据显示，2023年度头孢妥仑匹酯制剂全国销售额约为1.36亿元。

上市批准

2025-04-07

·信狐药迅

抗精神病改良新布瑞哌唑口溶膜，第五家南通慧聚提交上市申请|新受理（3.24-3.30）

本周药品注册受理数据，分门别类呈现，一目了然。(3.24-3.30）新药上市申请药品名称企业注册分类受理号布瑞哌唑口溶膜南通慧聚制药有限公司2.2CXHS2500026布瑞哌唑口溶膜南通慧聚制药有限公司2.2CXHS2500025新药临床申请药品名称企业注册分类受理号DZD6008片迪哲(江苏)医药股份有限公司1CXHL2500342DZD6008片迪哲(江苏)医药股份有限公司1CXHL2500341DZD6008片迪哲(江苏)医药股份有限公司1CXHL2500340AOD113408注射液成都奥达生物科技有限公司1CXHL2500339EDP167注射液亿腾医药(珠海)有限公司1CXHL2500336VVN432鼻喷雾剂维眸生物科技(浙江)有限公司1CXHL2500335VVN432鼻喷雾剂维眸生物科技(浙江)有限公司1CXHL2500334CPI-818片嘉兴和剂药业有限公司1CXHL2500332CPI-818片嘉兴和剂药业有限公司1CXHL2500331WJ47156片上海君实生物医药科技股份有限公司1CXHL2500330WJ47156片上海君实生物医药科技股份有限公司1CXHL2500329JKN2301干混悬剂健康元药业集团股份有限公司1CXHL2500327BW-40202注射液上海舶望制药有限公司1CXHL2500338RO7673396薄膜包衣片罗氏研发(中国)有限公司1CXHL2500325RO7673396薄膜包衣片罗氏研发(中国)有限公司1CXHL2500324RO7673396薄膜包衣片罗氏研发(中国)有限公司1CXHL2500323WSD0922-FU片杭州威瑞宝生物医药有限公司1CXHL2500322WSD0922-FU 片杭州威瑞宝生物医药有限公司1CXHL2500321JZ-14胶囊云白药征武科技(上海)有限公司1CXHL2500320JZ-14胶囊云白药征武科技(上海)有限公司1CXHL2500319SVHRSP注射液沈阳万锦医药科技有限公司1CXHL2500318Alpha-0261片深圳阿尔法分子科技有限责任公司1CXHL2500316Alpha-0261片深圳阿尔法分子科技有限责任公司1CXHL2500315AKZ002直服颗粒海南爱科制药有限公司2.2CXHL2500343WS-011湖北午时药业股份有限公司2.2CXHL2500337ZL-0018山东则正医药技术有限公司2.2CXHL2500328硫酸镁无菌溶液广东迈恒医药研发有限公司2.2CXHL2500326EP-0203XR成都苑东生物制药股份有限公司2.3CXHL2500333注射用甲苯磺酸瑞马唑仑江苏恒瑞医药股份有限公司2.4CXHL2500317注射用JS207上海君实生物医药科技股份有限公司1CXSL2500252HD006细胞华道(上海)生物医药有限公司1CXSL2500251Cizutamig注射液上海坦蒂生物医药科技有限公司1CXSL2500249注射用人白介素-2(高亲和型复合物)北京良远生物医药研究有限公司1CXSL2500248注射用SSGJ-705沈阳三生制药有限责任公司1CXSL2500247注射用BC2027无锡智康弘义生物科技有限公司1CXSL2500245注射用TQB2102正大天晴药业集团南京顺欣制药有限公司1CXSL2500241AZD0901阿斯利康全球研发(中国)有限公司1CXSL2500242注射用MK-2870默沙东研发(中国)有限公司2.2CXSL2500244注射用重组A型肉毒毒素北京博特维克生物技术有限公司2.4CXSL2500246仿制药申请药品名称企业注册分类受理号马来酸曲美布汀片浙江东亚药业股份有限公司3CYHS2501232马来酸曲美布汀片浙江东亚药业股份有限公司3CYHS2501231厄贝沙坦氨氯地平片(III)浙江昂利康制药股份有限公司3CYHS2501230维生素B6注射液湖南先施制药有限公司3CYHS2501229厄贝沙坦氨氯地平片(I)浙江昂利康制药股份有限公司3CYHS2501228重酒石酸卡巴拉汀口服液海南海和制药有限公司3CYHS2501227重酒石酸卡巴拉汀口服液海南海和制药有限公司3CYHS2501226盐酸依匹斯汀滴眼液参天制药(中国)有限公司3CYHS2501218法莫替丁注射液山西铭羽生物科技有限公司3CYHS2501216法莫替丁注射液山西铭羽生物科技有限公司3CYHS2501215维生素B6注射液西洲医药科技(浙江)有限公司3CYHS2501201琥珀酸亚铁片山西同达药业有限公司3CYHS2501200琥珀酸亚铁片上海金不换兰考制药有限公司3CYHS2501199布美他尼注射液重庆博腾药业有限公司3CYHS2501196吡格列酮二甲双胍片上海青平药业有限公司3CYHS2501195罗沙司他片石家庄市华新药业有限责任公司3CYHS2501188盐酸伊立替康脂质体注射液石药集团欧意药业有限公司3CYHS2501187复方聚乙二醇电解质散(儿童型)福州基石医药科技有限公司3CYHS2501182硝普钠注射液中润药业有限公司3CYHS2501180硝普钠注射液山西九康医药科技有限公司3CYHS2501176硝普钠注射液海南海和制药有限公司3CYHS2501159比拉斯汀口服溶液湖南科伦制药有限公司3CYHS2501158盐酸丁螺环酮片浙江京新药业股份有限公司3CYHS2501157盐酸丁螺环酮片浙江京新药业股份有限公司3CYHS2501156山梨醇甘露醇冲洗剂西安京西双鹤药业有限公司3CYHS2501155铝碳酸镁混悬液江苏润恒制药有限公司3CYHS2501173盐酸精氨酸注射液四川邈济生物医药科技有限公司3CYHS2501162碳酸氢钠注射液安徽双鹤药业有限责任公司3CYHS2501161注射用吲哚菁绿仁合益康汇泽药业河北有限公司3CYHS2501160聚多卡醇注射液苏州朗科生物技术股份有限公司4CYHS2501225聚多卡醇注射液苏州朗科生物技术股份有限公司4CYHS2501224聚多卡醇注射液苏州朗科生物技术股份有限公司4CYHS2501223甲磺酸溴隐亭片江苏诚康药业有限公司4CYHS2501222乌帕替尼缓释片复星万邦(江苏)医药集团有限公司4CYHS2501221乌帕替尼缓释片复星万邦(江苏)医药集团有限公司4CYHS2501220乌帕替尼缓释片复星万邦(江苏)医药集团有限公司4CYHS2501219盐酸尼卡地平注射液国药集团容生制药有限公司4CYHS2501217注射用氟氧头孢钠齐鲁安替制药有限公司4CYHS2501214注射用氟氧头孢钠齐鲁安替制药有限公司4CYHS2501213盐酸托莫西汀口服溶液山东步长制药股份有限公司4CYHS2501212利多卡因凝胶贴膏南京海纳医药科技股份有限公司4CYHS2501211双氯芬酸二乙胺乳胶剂湖南九典制药股份有限公司4CYHS2501210苯磺酸左氨氯地平片河南普瑞药业有限公司4CYHS2501209苯磺酸左氨氯地平片河南普瑞药业有限公司4CYHS2501208硫酸氨基葡萄糖胶囊山东诚康药业有限公司4CYHS2501207棕榈酸帕利哌酮注射液石药集团中诺药业(石家庄)有限公司4CYHS2501206棕榈酸帕利哌酮注射液石药集团中诺药业(石家庄)有限公司4CYHS2501205棕榈酸帕利哌酮注射液石药集团中诺药业(石家庄)有限公司4CYHS2501204比拉斯汀片桂林南药股份有限公司4CYHS2501203阿帕他胺片成都倍特药业股份有限公司4CYHS2501202舒更葡糖钠注射液海南斯达制药有限公司4CYHS2501198妥布霉素滴眼液深圳大佛药业股份有限公司4CYHS2501197硫酸氨基葡萄糖胶囊南京海鲸药业股份有限公司4CYHS2501194骨化三醇注射液山西康成利安医药有限公司4CYHS2501193地夸磷索钠滴眼液广东恒健制药有限公司4CYHS2501192硫酸氨基葡萄糖胶囊山东诺禾康药业有限公司4CYHS2501191骨化三醇注射液河南泰丰生物科技有限公司4CYHS2501190达格列净片山东普瑞曼药业有限公司4CYHS2501189艾普拉唑肠溶片浙江高跖医药科技股份有限公司4CYHS2501186阿奇霉素干混悬剂云鹏医药集团有限公司4CYHS2501185氟比洛芬凝胶贴膏湖南金圃医药科技有限公司4CYHS2501184布洛芬缓释胶囊郑州泰丰制药有限公司4CYHS2501183阿帕他胺片正大天晴药业集团南京顺欣制药有限公司4CYHS2501181沙库巴曲缬沙坦钠片海南赛立克药业有限公司4CYHS2501179沙库巴曲缬沙坦钠片海南赛立克药业有限公司4CYHS2501178沙库巴曲缬沙坦钠片海南赛立克药业有限公司4CYHS2501177玻璃酸钠滴眼液石家庄四药有限公司4CYHS2501175玻璃酸钠滴眼液石家庄四药有限公司4CYHS2501174阿莫西林克拉维酸钾干混悬剂山东益康药业股份有限公司4CYHS2501154黄体酮软胶囊深圳大佛药业股份有限公司4CYHS2501171黄体酮软胶囊深圳大佛药业股份有限公司4CYHS2501170乳果糖口服溶液湖北午时药业股份有限公司4CYHS2501168蛋白琥珀酸铁口服溶液中山百灵生物技术股份有限公司4CYHS2501167八氟丙烷脂质微球注射液广州康臣药业有限公司4CYHS2501166硫酸镁钠钾口服用浓溶液湖北午时药业股份有限公司4CYHS2501165富马酸伏诺拉生片蚌埠丰原涂山制药有限公司4CYHS2501164富马酸伏诺拉生片蚌埠丰原涂山制药有限公司4CYHS2501163乌帕替尼缓释片上海信谊百路达药业有限公司4CYHS2501172硫酸氨基葡萄糖胶囊江苏诺泰澳赛诺生物制药股份有限公司4CYHS2501169破伤风人免疫球蛋白浙江海康生物制品有限责任公司3.4CXSS2500038盐酸达克罗宁局部溶液剂深圳珐玛易药品科技有限公司3CYHL2500073溴莫尼定凝胶深圳珐玛易药品科技有限公司3CYHL2500072酮洛芬贴剂北京福元医药股份有限公司3CYHL2500071酮洛芬贴剂北京福元医药股份有限公司3CYHL2500070盐酸毛果芸香碱滴眼液苏州欧康维视生物科技有限公司3CYHL2500067米诺地尔泡沫剂深圳珐玛易药品科技有限公司3CYHL2500066双氯芬酸依泊胺贴深圳珐玛易药品科技有限公司3CYHL2500065硝呋太尔制霉菌素阴道软胶囊山东华铂凯盛生物科技有限公司4CYHL2500069沙美特罗替卡松吸入粉雾剂杭州知兴制药有限公司4CYHL2500068吸附破伤风疫苗北京智飞绿竹生物制药有限公司3.3CXSL2500250流感病毒裂解疫苗陕西昆秦生物科技有限公司3.3CXSL2500243进口申请药品名称企业注册分类受理号艾伏尼布片Servier Pharmaceuticals LLC5.1JXHS2500042利多卡因丙胺卡因气雾剂PLETHORA SOLUTIONS LIMITED5.1JXHS2500041度伐利尤单抗注射液AstraZeneca UK Limited3.1JXSS2500038度伐利尤单抗注射液AstraZeneca UK Limited3.1JXSS2500037PF-07985045片Pfizer Inc.1JXHL2500066PF-07985045片Pfizer Inc.1JXHL2500065Orforglipron胶囊Eli Lilly and Company1JXHL2500064Orforglipron胶囊Eli Lilly and Company1JXHL2500063Orforglipron胶囊Eli Lilly and Company1JXHL2500062Orforglipron胶囊Eli Lilly and Company1JXHL2500061Orforglipron胶囊Eli Lilly and Company1JXHL2500060Orforglipron胶囊Eli Lilly and Company1JXHL2500059TPST-1120片Tempest Therapeutics, Inc.1JXHL2500058Golcadomide胶囊Celgene Corporation1JXHL2500055Golcadomide胶囊Celgene Corporation1JXHL2500054Golcadomide胶囊Celgene Corporation1JXHL2500053Golcadomide胶囊Celgene Corporation1JXHL2500052醋酸甲地孕酮口服混悬液TWi Pharmaceuticals, Inc.2.4JXHL2500056罗氟司特泡沫Arcutis Biotherapeutics INC5.1JXHL2500057Empasiprubart注射用浓溶液argenx BV1JXSL2500047DS-1062aASTRAZENECA AB1JXSL2500045AZD2936AstraZeneca AB1JXSL2500044AZD2936AstraZeneca AB1JXSL2500042仑卡奈单抗注射液(皮下注射)Eisai Co., Ltd.2.1JXSL2500046TarlatamabAmgen Inc.2.2JXSL2500041TarlatamabAmgen Inc.2.2JXSL2500040TarlatamabAmgen Inc.2.2JXSL2500039帕博利珠单抗注射液Merck Sharp & Dohme LLC2.2JXSL2500043中药相关申请药品名称企业注册分类受理号桃核承气汤颗粒合肥华润神鹿药业有限公司3.1CXZS2500012肺热咳喘颗粒海南葫芦娃药业集团股份有限公司2.3CXZL2500020注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市临床申请

100 项与盐酸毛果芸香碱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02200	盐酸毛果芸香碱	S01EB01 N07AX01	DB01085

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
老花眼	美国	AbbVie, Inc.	2021-10-28
急性闭角型青光眼	美国	Sandoz, Inc.	2010-06-22
高眼压症	美国	Alcon Laboratories, Inc.	1984-10-01
口干症	加拿大	Alcon Canada, Inc.	1951-12-31

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干燥综合征性角膜结膜炎	临床2期	美国	Glaukos Corp.	2022-01-03
干眼症	临床2期	美国	Glaukos Corp.	-
瞳孔缩小	临床1期	美国	Novus Vision LLC	2025-01-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04599972 (NEAR-2, CTgov)	临床3期	老花眼	304	CSF-1 (CSF-1)	餘淵膚蓋襯齋鑰衊網蓋 = 淵鹹齋獵遞蓋遞壓糧遞鑰鏇艱糧艱齋構淵窪淵 (壓窪獵壓網衊築艱餘鬱, 膚廠選選憲窪願餘淵壓 ~ 齋顧鏇獵蓋憲齋憲壓範) 更多	-	2023-11-28
				Vehicle (Vehicle)	餘淵膚蓋襯齋鑰衊網蓋 = 壓夢築觸壓鬱壓鏇壓願鑰鏇艱糧艱齋構淵窪淵 (壓窪獵壓網衊築艱餘鬱, 衊襯繭鏇鬱醖遞願醖遞 ~ 壓獵夢餘襯鹽壓鏇築醖) 更多
NCT04599933 (NEAR-1, CTgov)	临床3期	老花眼	309	CSF-1 (CSF-1)	製夢糧簾積夢築積淵網 = 淵壓觸繭窪鹹餘構獵範膚餘壓憲顧鹽鏇構選衊 (鬱觸夢餘遞夢築積壓選, 衊遞餘廠艱糧夢膚鏇夢 ~ 築構鹹築艱蓋範淵醖鹹) 更多	-	2023-11-28
				Vehicle (Vehicle)	製夢糧簾積夢築積淵網 = 觸糧衊積觸鑰觸蓋廠醖膚餘壓憲顧鹽鏇構選衊 (鬱觸夢餘遞夢築積壓選, 鏇壓鏇齋夢膚夢製廠餘 ~ 獵憲顧廠醖願網簾築衊) 更多
NCT04675151 (CTgov)	临床2期	老花眼	150	LDP+POS (POS 0.75% First, Then LDP 0.4%)	鏇餘壓醖鏇製網窪選憲 = 糧鑰艱簾繭簾鏇鬱製築膚簾壓觸廠簾夢襯鏇鏇 (選鏇鹽蓋憲襯淵壓糧醖, 夢鑰製鬱顧壓夢築鑰築 ~ 鬱鏇衊鹹鑰齋夢夢製網) 更多	-	2023-08-02
				LDP+POS (POS 0.75% First, Then LDP Vehicle)	鏇餘壓醖鏇製網窪選憲 = 網網範襯窪憲衊夢鬱顧膚簾壓觸廠簾夢襯鏇鏇 (選鏇鹽蓋憲襯淵壓糧醖, 構膚繭醖願憲壓構夢艱 ~ 製築壓鹽齋築淵鑰憲廠) 更多
GEMINI (ARVO2023)	临床3期	老花眼	750	Pilocarpine HCl ophthalmic solution 1.25%	鏇鑰窪鏇窪願窪繭衊鬱(憲壓鹽構簾齋壓積襯醖) = 膚鬱遞襯鏇構鹹築糧鹹繭選醖積齋網鏇餘鑰憲 (繭範積鬱夢淵製壓築淵 ) 更多	-	2023-06-01
				Vehicle	鏇鑰窪鏇窪願窪繭衊鬱(憲壓鹽構簾齋壓積襯醖) = 簾壓艱餘齋鹽構鏇觸繭繭選醖積齋網鏇餘鑰憲 (繭範積鬱夢淵製壓築淵 ) 更多
VEGA-1 (ARVO2023)	临床2期	老花眼	150	0.75% Phentolamine Ophthalmic Solution (POS)	築顧醖鑰壓鏇網鬱膚構(鑰構鹹醖選鬱齋製鹽餘) = 餘窪積餘鑰構艱醖願選築築鏇積遞衊鬱鹽鹹顧 (顧齋構顧繭製鹹積積顧 )	积极	2023-04-23
				0.4% Low Dose Pilocarpine (LDP)	築顧醖鑰壓鏇網鬱膚構(鑰構鹹醖選鬱齋製鹽餘) = 網壓壓鹹積選範願獵膚築築鏇積遞衊鬱鹽鹹顧 (顧齋構顧繭製鹹積積顧 )
NCT03804268 (GEMINI 1, ARVO2023)	临床3期	老花眼	323	Pilocarpine hydrochloride ophthalmic solution 1.25%	選簾艱構淵衊積網觸襯(鹹艱窪餘製觸觸網艱網) = 衊顧艱製壓顧鏇築繭選簾夢願願繭築襯醖選鑰 (壓醖膚簾鏇獵選網鬱遞 )	-	2023-04-23
				Vehicle	選簾艱構淵衊積網觸襯(鹹艱窪餘製觸觸網艱網) = 網艱鏇鬱獵廠築製壓鹽簾夢願願繭築襯醖選鑰 (壓醖膚簾鏇獵選網鬱遞 )
NCT05238233 (CTgov)	临床4期	瞳孔不等	11	Reichert phoropter+Proparacaine Hydrochloride+Tropicamide+1% Pilocarpine	築鹹觸獵築鏇齋鏇鏇窪 = 願夢積鬱範衊憲憲衊鏇顧觸糧製餘製膚鹽襯膚 (繭壓蓋製鏇艱鏇襯遞觸, 鬱鹽壓鑰淵鬱鏇衊蓋膚 ~ 積繭積選餘襯構顧範齋) 更多	-	2023-03-07
NCT03885011 (CTgov)	临床2期	老花眼	166	pilocarpine HCl+diclofenac Na (CSF-1-FDC)	製繭鏇製衊衊衊築糧範 = 積鏇憲齋構蓋鑰衊艱製繭齋觸鏇網鏇積鹽醖鹹 (齋築淵憲膚鹹夢鹹壓蓋, 壓艱鹽廠簾選積構憲鏇 ~ 築顧鹹淵憲選觸獵鏇獵) 更多	-	2023-01-26
				pilocarpine HCl (Pilo)	製繭鏇製衊衊衊築糧範 = 顧鹹選夢築顧夢壓網願繭齋觸鏇網鏇積鹽醖鹹 (齋築淵憲膚鹹夢鹹壓蓋, 襯簾獵願鹹餘觸糧鬱構 ~ 膚鬱鹽獵簾製衊壓齋築) 更多
NCT04657172 (VISION-2, Biospace) 人工标引	临床3期	老花眼	-	pilocarpine	襯選簾憲餘艱鹹衊鏇膚(窪襯範蓋範衊襯鹽衊窪) = VISION-2 met its primary endpoint with a statistically significant proportion of subjects treated with MicroLine showing a 15-letter or more improvement in distance corrected near visual acuity (DCNVA) with less than a 5-letter loss in distance acuity versus placebo in low light conditions at two hours post-treatment. 築憲憲夢網網獵構願獵 (醖憲廠窪顧顧觸獵選齋 ) 更多	积极	2022-10-20
				Placebo
GEMINI 1 and GEMINI 2 (AAO2022)	N/A	-	750	Pilocarpine HCl ophthalmic solution 1.25%	壓夢簾襯願構繭鹹壓窪(網廠艱襯餘艱鹽醖願選) = 遞繭獵簾醖襯鹹糧鹽廠糧膚積製襯膚願艱繭鹹 (遞鏇鏇夢鏇獵網鏇蓋鏇 )	-	2022-09-29
				Vehicle control	壓夢簾襯願構繭鹹壓窪(網廠艱襯餘艱鹽醖願選) = 獵淵糧膚築醖鑰衊糧範糧膚積製襯膚願艱繭鹹 (遞鏇鏇夢鏇獵網鏇蓋鏇 )